Recap: Johnson & Johnson Q2 Earnings

Shares of Johnson & Johnson JNJ moved higher by 0.1% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 35.27% year over year to $1.67, which beat the estimate of $1.48.

Revenue of $18,336,000,000 decreased by 10.83% year over year, which beat the estimate of $17,500,000,000.

Guidance

Q3 EPS expected between $7.75 and $7.95.

The upcoming fiscal year's revenue expected to be between $79,900,000,000 and $81,400,000,000.

Conference Call Details

Date: Jul 16, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/y8jhbf4v

Recent Stock Performance

52-week high: $157.00

Company's 52-week low was at $109.16

Price action over last quarter: Up 0.77%

Company Overview

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!